Today, Nanion, a German
Private Limited Company and was founded in 2002 as a spin-off from the Center
for Nanoscience (CeNS) of the University of Munich, announces the late-stage
development of a new automated patch clamp platform: the SyncroPatch 96. Developed
to meet the throughput demands of industrial ion channel drug screening and
safety profiling, and with a price-per-data-point compatible with screening
standards, the SyncroPatch 96 will offer the highest throughput in the market
for high quality HTS-oriented ion channel screening.
Following the successful market introduction of two automated patch clamp
devices, the Port-a-Patch (2004) and the Patchliner (2006), Nanion now introduces
the SyncroPatch 96. Nanion's Patchliner and Port-a-Patch platforms enjoy great
popularity in both academic and industrial settings and have received enthusiastic
user feedback in customer surveys such as the HTStec report. Building on their
success, the new SyncroPatch 96 vastly increases throughput while reducing the
cost per data point to a level compatible with industrial ion channel screening
requirements.
"There is a gap between the demands in ion channel drug screening and
the capability of the high quality automated patch clamp platforms currently
available on the market. Pharmaceutical companies want higher throughput and
lower cost per data point, whilst maintaining data quality. The SyncroPatch96
will fill this gap, by providing high throughput, high quality patch clamp recordings,
at a low enough cost to keep screeners happy," says Dr. Niels Fertig, CEO
of Nanion.
The SyncroPatch 96 acquires simultaneous recordings from 96 individual cells
in a well-plate format and allows for screening of both ligand- and voltage-gated
ion channels. The platform supports giga-seal recordings, continuous recording
during compound application and addition of multiple compounds to each of the
96 cells. The SyncroPatch 96 will be launched in 2009.
Posted November 21st, 2008